deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02978404

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

A Phase II, Multi-centre Study, of Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases From Non-small Cell Lung Cancer and Renal Cell Cancer

Sponsor: Bristol-Myers Squibb

Conditions Brain Metastases, Adult Clear-Cell Metastatic Renal Cell Carcinoma Melanoma Non Small Cell Lung Cancer Metastatic Small Cell Lung Cancer
Interventions Nivolumab Radiosurgery
Updated 16 times since 2017 Last updated: Jun 27, 2024 Started: Jun 2, 2017 Primary completion: Jan 31, 2021 Completion: Dec 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Brain Metastases, Adult and Clear-Cell Metastatic Renal Cell Carcinoma, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 16 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Oct 2019 · 7 months · monthly snapshot~Oct 2019 – ~Jul 2020 · 9 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Mar 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 11 earlier versions

  1. Sep 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Oct 2019 — Jul 2020 [monthly]

    Recruiting PHASE2

  6. Mar 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  7. Sep 2018 — Mar 2019 [monthly]

    Recruiting PHASE2

  8. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  9. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  10. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Jan 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Centre hospitalier de l'Université de Montréal (CHUM)
Data source: Centre hospitalier de l'Université de Montréal (CHUM)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations